Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8e71233d46c313ac971fc4f9e4aa4d |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0202 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 |
filingDate |
2017-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a106ba237bc47516e621a770c6026ee |
publicationDate |
2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-201818970-A |
titleOfInvention |
Targeted delivery of nicotinic adenine dinucleotide dinucleotide remedial synthesis (SALVAGE PATHWAY) inhibitor |
abstract |
The invention discloses a compound and a composition in which a NAMPT drug unit is connected to a targeting ligand unit through a unit capable of releasing a NAMPT inhibitor compound or a derivative thereof from a targeting site. The present invention also discloses methods for using the complexes and compositions of the present invention to treat diseases characterized by targeting abnormal cells, such as cancer or autoimmune diseases. |
priorityDate |
2016-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |